WhiteOak Capital Pharma and Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹16.57-0.77%
08 Jul 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (23.1%)
Mid Cap (19.9%)
Small Cap (57.0%)
Historical Asset Allocation
| Asset | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 | 31 Dec 2025 |
|---|---|---|---|---|---|---|
| Equity | 99.10% | 99.17% | 98.05% | 98.70% | 98.66% | 98.58% |
| Debt | 7.95% | 7.21% | 3.78% | 5.39% | 2.17% | 6.36% |
| Others (incl. cash) | -7.04% | -6.38% | -1.83% | -4.09% | -0.83% | -4.95% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
59
P/E Ratio
45.63
P/B Ratio
6.59
Top Holding %
9.56%
Top 5 Holdings %
29.56%
Top 10 Holdings %
46.21%
AUM
₹664 Cr
Expense Ratio
1.20%
Since Inception
23.20%
Max Drawdown
-0.15%
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 3,52,927 | 63.5 | 9.56% | -0.91%↓ |
| JB Chemicals & Pharmaceuticals Ltd. | Healthcare | 2,08,357 | 45.16 | 6.80% | 0.26%↑ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 39,235 | 32.08 | 4.83% | 0.81%↑ |
| Laurus Labs Ltd. | Healthcare | 2,15,746 | 29.38 | 4.43% | 0.30%↑ |
| Fortis Healthcare Ltd. | Healthcare | 2,80,524 | 26.05 | 3.92% | -0.20%↓ |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 3,00,749 | 22.82 | 3.44% | 0.31%↑ |
| Divis Laboratories Ltd. | Healthcare | 32,793 | 21.86 | 3.29% | -0.82%↓ |
| Sai Life Sciences Ltd. | Healthcare | 1,81,601 | 21.07 | 3.17% | 0.15%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 1,94,507 | 18.77 | 2.83% | -0.48%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 1,21,757 | 17.37 | 2.62% | -0.71%↓ |
| Neuland Laboratories Ltd. | Healthcare | 9,841 | 16.82 | 2.53% | -0.11%↓ |
| Acutaas Chemicals Ltd. | Healthcare | 52,193 | 16.35 | 2.46% | 0.01%↑ |
| CORONA Remedies Ltd. | Healthcare | 91,998 | 15.43 | 2.32% | -0.11%↓ |
| Dr. Lal Pathlabs Ltd. | Healthcare | 87,152 | 14.01 | 2.11% | 0.82%↑ |
| Thyrocare Technologies Ltd. | Healthcare | 2,69,555 | 13.65 | 2.06% | 0.08%↑ |
| Gland Pharma Ltd. | Healthcare | 58,844 | 13.24 | 1.99% | - |
| Narayana Hrudayalaya Ltd. | Healthcare | 65,986 | 12.5 | 1.88% | -0.05%↓ |
| Aster DM Healthcare Ltd. | Healthcare | 1,63,957 | 11.94 | 1.80% | - |
| Shaily Engineering Plastics Ltd. | Materials | 38,842 | 11.61 | 1.75% | 0.44%↑ |
| Ajanta Pharma Ltd. | Healthcare | 38,038 | 11.14 | 1.68% | -0.10%↓ |
1 / 3
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 | 31 Dec 2025 |
|---|---|---|---|---|---|---|
| Healthcare | 94.12% | 93.65% | 92.98% | 93.24% | 92.82% | 94.41% |
| Chemicals | 2.49% | 3.24% | 3.00% | 3.06% | 2.93% | 2.11% |
| Materials | 1.75% | 1.31% | 1.58% | 1.78% | 1.90% | 2.07% |
| Services | 0.74% | 0.96% | 0.48% | 0.61% | 1.02% | - |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
22.1 / 100
Weighted average Value score is 22.1. This indicates that portfolio is relatively overvalued using composite of value measures.
Price Momentum score
81.4 / 100
Weighted average Price Momentum score is 81.4. This indicates that portfolio has high momentum using composite of momentum measures.
Quality score
88.0 / 100
Weighted average Quality score is 88.0. This indicates that portfolio has high quality using composite of quality measures.
QVM score
75.3 / 100
Weighted average QVM score is 75.3. This indicates that portfolio has high QVM score and hence could be considered for investment.
Red Flags
Frequently Asked Questions
What are the top holdings of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The top holdings of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth sorted by portfolio weight are listed in the Top Portfolio Holdings section of the Holdings tab.
How many stocks does WhiteOak Capital Pharma and Healthcare Fund Direct-Growth hold in its portfolio?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth holds 59 securities in its portfolio. The top 5 holdings account for 29.56% of the portfolio and the top 10 for 46.21%.
What is the sector allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The sector allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is in the Sector Allocation section, showing each industry's weight in the portfolio.
What is the equity and debt allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
As of 31 May 2026, WhiteOak Capital Pharma and Healthcare Fund Direct-Growth has 99.10% in equity, 7.95% in debt and -7.04% in cash/others. This asset mix determines the fund's overall risk-return profile.
What is the market cap allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's equity portfolio — Large Cap: 23.10%, Mid Cap: 19.89%, Small Cap: 57.01%. Market cap allocation determines the fund's risk profile — large cap offers stability while mid and small cap offer higher growth potential with higher volatility.
Is WhiteOak Capital Pharma and Healthcare Fund Direct-Growth a concentrated or diversified fund?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth holds 59 securities, with the top 10 accounting for 46.21% of the portfolio and the top 5 for 29.56%. This is a moderately diversified fund balancing conviction positions with risk spread.
What is the credit quality of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The credit quality breakdown of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's debt portfolio is in the Credit Rating section. For equity-oriented funds, this section may not be applicable.
How often does WhiteOak Capital Pharma and Healthcare Fund Direct-Growth change its portfolio?
The portfolio currently holds 59 securities with the top 10 accounting for 46.21% as of 31 May 2026. Portfolio turnover reflects how actively the fund manager trades. A high turnover increases transaction costs while a low turnover reflects a buy-and-hold approach. Historical asset allocation snapshots across multiple dates are in the Holdings Analysis section.
What is the PE ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's portfolio?
The weighted average PE ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's portfolio is 45.63 and the PB ratio is 6.59. These metrics reflect the overall valuation and interest rate sensitivity of the portfolio.
When is the latest portfolio disclosure for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The latest portfolio disclosure for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is as of 31 May 2026. Mutual funds and ETFs in India are required to disclose their full portfolio monthly, within 10 business days of month-end. You can switch between historical disclosure dates using the date selector in the Top Portfolio Holdings section.